Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression
Acta Pharmaceutica Sinica B
; (6): 4008-4019, 2021.
Article
in En
| WPRIM
| ID: wpr-922456
Responsible library:
WPRO
ABSTRACT
Cholangiocarcinoma (CCA) has emerged as an intractable cancer with scanty therapeutic regimens. The aberrant activation of Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are reported to be common in CCA patients. However, the underpinning mechanism remains poorly understood. Deubiquitinase (DUB) is regarded as a main orchestrator in maintaining protein homeostasis. Here, we identified Josephin domain-containing protein 2 (JOSD2) as an essential DUB of YAP/TAZ that sustained the protein level through cleavage of polyubiquitin chains in a deubiquitinase activity-dependent manner. The depletion of JOSD2 promoted YAP/TAZ proteasomal degradation and significantly impeded CCA proliferation
Full text:
1
Database:
WPRIM
Type of study:
Prognostic_studies
Language:
En
Journal:
Acta Pharmaceutica Sinica B
Year:
2021
Document type:
Article